We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+2.67%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$46.3B
AUM Growth
+$3.2B
Cap. Flow
+$2.34B
Cap. Flow %
5.06%
Top 10 Hldgs %
17.9%
Holding
3,541
New
248
Increased
1,836
Reduced
1,143
Closed
207

Sector Composition

Rank Sector Weight
1 Technology 9.28%
2 Healthcare 9.23%
3 Financials 8.81%
4 Industrials 6.85%
5 Communication Services 6.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ILG
2576
DELISTED
ILG, Inc Common Stock
ILG
$374K ﹤0.01%
13,614
+3,105
+30% +$78.6K
TPYP icon
2577
Tortoise North American Pipeline ETF
TPYP
$859M
$372K ﹤0.01%
15,899
+2,868
+22% +$67.7K
FMS icon
2578
Fresenius Medical Care
FMS
$12.9B
$371K ﹤0.01%
7,682
-9,490
-55% -$437K
GLOB icon
2579
Globant
GLOB
$1.59B
$371K ﹤0.01%
8,542
+2,079
+32% +$80.4K
EVH icon
2580
Evolent Health
EVH
$458M
$370K ﹤0.01%
+14,608
New +$351K
IMO icon
2581
Imperial Oil
IMO
$60.7B
$370K ﹤0.01%
12,688
-1,080
-8% -$31.6K
ZTR
2582
Virtus Total Return Fund
ZTR
$338M
$370K ﹤0.01%
29,323
-10,208
-26% -$126K
GBL
2583
DELISTED
GAMCO Investors, Inc.
GBL
$370K ﹤0.01%
12,510
GCP
2584
DELISTED
GCP Applied Technologies Inc.
GCP
$370K ﹤0.01%
12,133
+791
+7% +$24.9K
CARS icon
2585
Cars.com
CARS
$704M
$369K ﹤0.01%
+13,844
New +$373K
WIA
2586
Western Asset Inflation-Linked Income Fund
WIA
$186M
$368K ﹤0.01%
32,555
+2,183
+7% +$24.7K
NXR
2587
DELISTED
NUVEEN ELECT TAX-FREE INC 3
NXR
$368K ﹤0.01%
25,151
+2,534
+11% +$36.9K
EGRX
2588
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$367K ﹤0.01%
4,655
+766
+20% +$62.6K
PBR icon
2589
Petrobras
PBR
$116B
$366K ﹤0.01%
45,835
+1,671
+4% +$14.9K
AAAP
2590
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$366K ﹤0.01%
9,381
+1,022
+12% +$38.5K
WES icon
2591
Western Midstream Partners
WES
$19.5B
$365K ﹤0.01%
8,489
-485
-5% -$21.3K
NYT icon
2592
New York Times
NYT
$10.3B
$363K ﹤0.01%
20,516
-90
-0.4% -$1.48K
CCJ icon
2593
Cameco
CCJ
$42.3B
$362K ﹤0.01%
39,729
-1,575
-4% -$15.7K
JJSF icon
2594
J&J Snack Foods
JJSF
$1.69B
$362K ﹤0.01%
2,744
+85
+3% +$11.3K
CHUY
2595
DELISTED
Chuy's Holdings, Inc. Common Stock
CHUY
$362K ﹤0.01%
15,479
+1,758
+13% +$48.5K
GPP
2596
DELISTED
Green Plains Partners LP
GPP
$362K ﹤0.01%
19,374
+2,091
+12% +$40.6K
KMF
2597
DELISTED
Kayne Anderson NextGen Energy & Infrastructure, Inc.
KMF
$362K ﹤0.01%
23,875
+157
+0.7% +$2.42K
GTLS
2598
DELISTED
Chart Industries
GTLS
$361K ﹤0.01%
10,388
+1,123
+12% +$39.2K
UMH
2599
UMH Properties
UMH
$1.35B
$361K ﹤0.01%
21,193
-58,689
-73% -$968K
NOAH
2600
Noah Holdings
NOAH
$600M
$360K ﹤0.01%
12,558
+770
+7% +$20.4K

Similar funds

Raymond James & Associates's Q2 2017 Portfolio in Review

As of Q2 2017, Raymond James & Associates held 3,541 positions worth $46.3B, up 7.4% from $43.1B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Raymond James & Associates deployed $2.34B of net new capital in Q2 2017, opening 248 new positions and adding to 1,836 existing holdings. Its largest new stake was DXC Technology: 324,843 shares worth $21.6M.

By sector, the portfolio is most concentrated in Technology at 9.3% of assets, down from 9.6% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Novartis, an estimated $53.7M trimmed.

  • Raymond James & Associates's largest Q2 2017 buy was DXC Technology: 324,843 shares worth $21.6M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q2 2017, an estimated $308M increase.
  • Raymond James & Associates's biggest Q2 2017 reduction was Novartis, cutting an estimated $53.7M.
  • Raymond James & Associates fully exited Energy Transfer Partners L.p. in Q2 2017, selling an estimated $24.9M.
  • Raymond James & Associates's ten largest holdings make up 18% of its $46.3B portfolio in Q2 2017.
  • Raymond James & Associates opened 248 new positions and closed 207 in Q2 2017.
  • Raymond James & Associates's portfolio value rose 7.4% quarter-over-quarter to $46.3B.

Based on Raymond James & Associates's 13F filing for Q2 2017, filed 14 Aug 2017.